nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—breast cancer	0.2	1	CbGaD
Naltrexone—UGT1A1—Irinotecan—breast cancer	0.0866	0.239	CbGbCtD
Naltrexone—ABCB1—Toremifene—breast cancer	0.0612	0.169	CbGbCtD
Naltrexone—ABCB1—Lapatinib—breast cancer	0.0447	0.124	CbGbCtD
Naltrexone—ABCB1—Vinorelbine—breast cancer	0.0248	0.0685	CbGbCtD
Naltrexone—ABCB1—Tamoxifen—breast cancer	0.0224	0.0618	CbGbCtD
Naltrexone—ABCB1—Mitoxantrone—breast cancer	0.0218	0.0603	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—breast cancer	0.0193	0.0533	CbGbCtD
Naltrexone—ABCB1—Paclitaxel—breast cancer	0.0174	0.0481	CbGbCtD
Naltrexone—ABCB1—Irinotecan—breast cancer	0.0172	0.0475	CbGbCtD
Naltrexone—ABCB1—Vinblastine—breast cancer	0.0153	0.0422	CbGbCtD
Naltrexone—ABCB1—Docetaxel—breast cancer	0.0126	0.0348	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—breast cancer	0.00938	0.0259	CbGbCtD
Naltrexone—ABCB1—Methotrexate—breast cancer	0.00909	0.0251	CbGbCtD
Naltrexone—Methylnaltrexone—CYP2D6—breast cancer	0.000406	0.0819	CrCbGaD
Naltrexone—Buprenorphine—ABCG2—breast cancer	0.000382	0.077	CrCbGaD
Naltrexone—Naloxone—ESR1—breast cancer	0.000371	0.0749	CrCbGaD
Naltrexone—Hydromorphone—PTGS1—breast cancer	0.000322	0.065	CrCbGaD
Naltrexone—Oxymorphone—CYP2D6—breast cancer	0.000303	0.0611	CrCbGaD
Naltrexone—Hydrocodone—CYP2D6—breast cancer	0.000264	0.0534	CrCbGaD
Naltrexone—Oxymorphone—CYP3A4—breast cancer	0.00026	0.0524	CrCbGaD
Naltrexone—Oxycodone—CYP2D6—breast cancer	0.000241	0.0487	CrCbGaD
Naltrexone—Hydrocodone—CYP3A4—breast cancer	0.000227	0.0458	CrCbGaD
Naltrexone—Buprenorphine—CYP2D6—breast cancer	0.000222	0.0449	CrCbGaD
Naltrexone—Hydromorphone—CYP2D6—breast cancer	0.000219	0.0443	CrCbGaD
Naltrexone—Oxycodone—CYP3A4—breast cancer	0.000207	0.0418	CrCbGaD
Naltrexone—Buprenorphine—CYP3A4—breast cancer	0.000191	0.0385	CrCbGaD
Naltrexone—Naloxone—CYP3A4—breast cancer	0.000189	0.0382	CrCbGaD
Naltrexone—Hydromorphone—CYP3A4—breast cancer	0.000188	0.038	CrCbGaD
Naltrexone—Morphine—CYP2D6—breast cancer	0.000186	0.0376	CrCbGaD
Naltrexone—Naloxone—ALB—breast cancer	0.000165	0.0333	CrCbGaD
Naltrexone—Morphine—CYP3A4—breast cancer	0.00016	0.0323	CrCbGaD
Naltrexone—Buprenorphine—ABCB1—breast cancer	0.000159	0.0321	CrCbGaD
Naltrexone—Naloxone—ABCB1—breast cancer	0.000158	0.0318	CrCbGaD
Naltrexone—Morphine—ABCB1—breast cancer	0.000133	0.0269	CrCbGaD
Naltrexone—Dyspnoea—Docetaxel—breast cancer	4.86e-05	0.000154	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—breast cancer	4.85e-05	0.000153	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—breast cancer	4.85e-05	0.000153	CcSEcCtD
Naltrexone—Rash—Gemcitabine—breast cancer	4.84e-05	0.000153	CcSEcCtD
Naltrexone—Dermatitis—Gemcitabine—breast cancer	4.84e-05	0.000153	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—breast cancer	4.84e-05	0.000153	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—breast cancer	4.83e-05	0.000153	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—breast cancer	4.81e-05	0.000152	CcSEcCtD
Naltrexone—Headache—Gemcitabine—breast cancer	4.81e-05	0.000152	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Capecitabine—breast cancer	4.81e-05	0.000152	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—breast cancer	4.8e-05	0.000152	CcSEcCtD
Naltrexone—Vomiting—Fluorouracil—breast cancer	4.8e-05	0.000152	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—breast cancer	4.79e-05	0.000151	CcSEcCtD
Naltrexone—Insomnia—Capecitabine—breast cancer	4.77e-05	0.000151	CcSEcCtD
Naltrexone—Rash—Fluorouracil—breast cancer	4.76e-05	0.000151	CcSEcCtD
Naltrexone—Dermatitis—Fluorouracil—breast cancer	4.76e-05	0.000151	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—breast cancer	4.75e-05	0.00015	CcSEcCtD
Naltrexone—Paraesthesia—Capecitabine—breast cancer	4.74e-05	0.00015	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—breast cancer	4.74e-05	0.00015	CcSEcCtD
Naltrexone—Hypersensitivity—Paclitaxel—breast cancer	4.74e-05	0.00015	CcSEcCtD
Naltrexone—Headache—Fluorouracil—breast cancer	4.73e-05	0.00015	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—breast cancer	4.71e-05	0.000149	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—breast cancer	4.71e-05	0.000149	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—breast cancer	4.71e-05	0.000149	CcSEcCtD
Naltrexone—Dyspnoea—Capecitabine—breast cancer	4.71e-05	0.000149	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—breast cancer	4.7e-05	0.000149	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—breast cancer	4.7e-05	0.000149	CcSEcCtD
Naltrexone—Nausea—Mitoxantrone—breast cancer	4.68e-05	0.000148	CcSEcCtD
Naltrexone—Nausea—Irinotecan—breast cancer	4.68e-05	0.000148	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—breast cancer	4.67e-05	0.000148	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—breast cancer	4.66e-05	0.000148	CcSEcCtD
Naltrexone—Pain—Docetaxel—breast cancer	4.66e-05	0.000147	CcSEcCtD
Naltrexone—Constipation—Docetaxel—breast cancer	4.66e-05	0.000147	CcSEcCtD
Naltrexone—Back pain—Methotrexate—breast cancer	4.66e-05	0.000147	CcSEcCtD
Naltrexone—Chills—Epirubicin—breast cancer	4.64e-05	0.000147	CcSEcCtD
Naltrexone—Asthenia—Paclitaxel—breast cancer	4.61e-05	0.000146	CcSEcCtD
Naltrexone—Decreased appetite—Capecitabine—breast cancer	4.59e-05	0.000145	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—breast cancer	4.57e-05	0.000145	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—breast cancer	4.56e-05	0.000144	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Capecitabine—breast cancer	4.56e-05	0.000144	CcSEcCtD
Naltrexone—Fatigue—Capecitabine—breast cancer	4.55e-05	0.000144	CcSEcCtD
Naltrexone—Pruritus—Paclitaxel—breast cancer	4.55e-05	0.000144	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—breast cancer	4.54e-05	0.000144	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—breast cancer	4.53e-05	0.000143	CcSEcCtD
Naltrexone—Pain—Capecitabine—breast cancer	4.51e-05	0.000143	CcSEcCtD
Naltrexone—Constipation—Capecitabine—breast cancer	4.51e-05	0.000143	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—breast cancer	4.51e-05	0.000143	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—breast cancer	4.49e-05	0.000142	CcSEcCtD
Naltrexone—Nausea—Fluorouracil—breast cancer	4.49e-05	0.000142	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—breast cancer	4.48e-05	0.000142	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—breast cancer	4.47e-05	0.000141	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—breast cancer	4.46e-05	0.000141	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—breast cancer	4.46e-05	0.000141	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—breast cancer	4.44e-05	0.000141	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—breast cancer	4.44e-05	0.00014	CcSEcCtD
Naltrexone—Tension—Epirubicin—breast cancer	4.42e-05	0.00014	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—breast cancer	4.41e-05	0.00014	CcSEcCtD
Naltrexone—Diarrhoea—Paclitaxel—breast cancer	4.4e-05	0.000139	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—breast cancer	4.38e-05	0.000138	CcSEcCtD
Naltrexone—Back pain—Epirubicin—breast cancer	4.36e-05	0.000138	CcSEcCtD
Naltrexone—Feeling abnormal—Capecitabine—breast cancer	4.35e-05	0.000138	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—breast cancer	4.34e-05	0.000137	CcSEcCtD
Naltrexone—Malaise—Methotrexate—breast cancer	4.34e-05	0.000137	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—breast cancer	4.33e-05	0.000137	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—breast cancer	4.33e-05	0.000137	CcSEcCtD
Naltrexone—Gastrointestinal pain—Capecitabine—breast cancer	4.32e-05	0.000137	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—breast cancer	4.32e-05	0.000137	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—breast cancer	4.31e-05	0.000136	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—breast cancer	4.31e-05	0.000136	CcSEcCtD
Naltrexone—Chills—Doxorubicin—breast cancer	4.3e-05	0.000136	CcSEcCtD
Naltrexone—Dizziness—Paclitaxel—breast cancer	4.25e-05	0.000135	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—breast cancer	4.25e-05	0.000134	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—breast cancer	4.23e-05	0.000134	CcSEcCtD
Naltrexone—Cough—Methotrexate—breast cancer	4.2e-05	0.000133	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—breast cancer	4.2e-05	0.000133	CcSEcCtD
Naltrexone—Urticaria—Capecitabine—breast cancer	4.19e-05	0.000133	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—breast cancer	4.18e-05	0.000132	CcSEcCtD
Naltrexone—Abdominal pain—Capecitabine—breast cancer	4.17e-05	0.000132	CcSEcCtD
Naltrexone—Body temperature increased—Capecitabine—breast cancer	4.17e-05	0.000132	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—breast cancer	4.17e-05	0.000132	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—breast cancer	4.17e-05	0.000132	CcSEcCtD
Naltrexone—Agitation—Epirubicin—breast cancer	4.14e-05	0.000131	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—breast cancer	4.11e-05	0.00013	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—breast cancer	4.1e-05	0.00013	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—breast cancer	4.1e-05	0.00013	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—breast cancer	4.1e-05	0.00013	CcSEcCtD
Naltrexone—Tension—Doxorubicin—breast cancer	4.09e-05	0.000129	CcSEcCtD
Naltrexone—Vomiting—Paclitaxel—breast cancer	4.09e-05	0.000129	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—breast cancer	4.08e-05	0.000129	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.07e-05	0.000129	CcSEcCtD
Naltrexone—Malaise—Epirubicin—breast cancer	4.06e-05	0.000129	CcSEcCtD
Naltrexone—Rash—Paclitaxel—breast cancer	4.06e-05	0.000128	CcSEcCtD
Naltrexone—Dermatitis—Paclitaxel—breast cancer	4.05e-05	0.000128	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—breast cancer	4.05e-05	0.000128	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—breast cancer	4.05e-05	0.000128	CcSEcCtD
Naltrexone—Syncope—Epirubicin—breast cancer	4.04e-05	0.000128	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—breast cancer	4.03e-05	0.000128	CcSEcCtD
Naltrexone—Headache—Paclitaxel—breast cancer	4.03e-05	0.000127	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—breast cancer	4.02e-05	0.000127	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—breast cancer	4.01e-05	0.000127	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—breast cancer	3.98e-05	0.000126	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—breast cancer	3.96e-05	0.000125	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—breast cancer	3.96e-05	0.000125	CcSEcCtD
Naltrexone—Cough—Epirubicin—breast cancer	3.93e-05	0.000124	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—breast cancer	3.93e-05	0.000124	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—breast cancer	3.93e-05	0.000124	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—breast cancer	3.91e-05	0.000124	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—breast cancer	3.9e-05	0.000123	CcSEcCtD
Naltrexone—Infection—Methotrexate—breast cancer	3.9e-05	0.000123	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—breast cancer	3.89e-05	0.000123	CcSEcCtD
Naltrexone—Hypersensitivity—Capecitabine—breast cancer	3.89e-05	0.000123	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—breast cancer	3.87e-05	0.000122	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—breast cancer	3.86e-05	0.000122	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—breast cancer	3.85e-05	0.000122	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—breast cancer	3.84e-05	0.000121	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—breast cancer	3.84e-05	0.000121	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—breast cancer	3.84e-05	0.000121	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—breast cancer	3.83e-05	0.000121	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—breast cancer	3.82e-05	0.000121	CcSEcCtD
Naltrexone—Nausea—Paclitaxel—breast cancer	3.82e-05	0.000121	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—breast cancer	3.82e-05	0.000121	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.81e-05	0.000121	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—breast cancer	3.8e-05	0.00012	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—breast cancer	3.79e-05	0.00012	CcSEcCtD
Naltrexone—Asthenia—Capecitabine—breast cancer	3.79e-05	0.00012	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—breast cancer	3.76e-05	0.000119	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—breast cancer	3.75e-05	0.000119	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—breast cancer	3.75e-05	0.000118	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—breast cancer	3.74e-05	0.000118	CcSEcCtD
Naltrexone—Pruritus—Capecitabine—breast cancer	3.73e-05	0.000118	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—breast cancer	3.73e-05	0.000118	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—breast cancer	3.71e-05	0.000117	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—breast cancer	3.68e-05	0.000117	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—breast cancer	3.68e-05	0.000116	CcSEcCtD
Naltrexone—Oedema—Epirubicin—breast cancer	3.68e-05	0.000116	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—breast cancer	3.66e-05	0.000116	CcSEcCtD
Naltrexone—Infection—Epirubicin—breast cancer	3.65e-05	0.000116	CcSEcCtD
Naltrexone—Cough—Doxorubicin—breast cancer	3.64e-05	0.000115	CcSEcCtD
Naltrexone—Shock—Epirubicin—breast cancer	3.62e-05	0.000114	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—breast cancer	3.61e-05	0.000114	CcSEcCtD
Naltrexone—Diarrhoea—Capecitabine—breast cancer	3.61e-05	0.000114	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—breast cancer	3.61e-05	0.000114	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—breast cancer	3.6e-05	0.000114	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—breast cancer	3.6e-05	0.000114	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—breast cancer	3.59e-05	0.000114	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—breast cancer	3.58e-05	0.000113	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—breast cancer	3.57e-05	0.000113	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—breast cancer	3.55e-05	0.000112	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—breast cancer	3.55e-05	0.000112	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—breast cancer	3.55e-05	0.000112	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—breast cancer	3.55e-05	0.000112	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—breast cancer	3.55e-05	0.000112	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—breast cancer	3.54e-05	0.000112	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—breast cancer	3.53e-05	0.000112	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.52e-05	0.000111	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—breast cancer	3.51e-05	0.000111	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—breast cancer	3.5e-05	0.000111	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—breast cancer	3.5e-05	0.000111	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—breast cancer	3.49e-05	0.00011	CcSEcCtD
Naltrexone—Dizziness—Capecitabine—breast cancer	3.49e-05	0.00011	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—breast cancer	3.47e-05	0.00011	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—breast cancer	3.47e-05	0.00011	CcSEcCtD
Naltrexone—Rash—Docetaxel—breast cancer	3.44e-05	0.000109	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—breast cancer	3.43e-05	0.000109	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—breast cancer	3.43e-05	0.000109	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—breast cancer	3.42e-05	0.000108	CcSEcCtD
Naltrexone—Headache—Docetaxel—breast cancer	3.42e-05	0.000108	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—breast cancer	3.4e-05	0.000108	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—breast cancer	3.4e-05	0.000108	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—breast cancer	3.39e-05	0.000107	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—breast cancer	3.39e-05	0.000107	CcSEcCtD
Naltrexone—Infection—Doxorubicin—breast cancer	3.38e-05	0.000107	CcSEcCtD
Naltrexone—Pain—Methotrexate—breast cancer	3.36e-05	0.000106	CcSEcCtD
Naltrexone—Vomiting—Capecitabine—breast cancer	3.36e-05	0.000106	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—breast cancer	3.35e-05	0.000106	CcSEcCtD
Naltrexone—Shock—Doxorubicin—breast cancer	3.35e-05	0.000106	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—breast cancer	3.34e-05	0.000106	CcSEcCtD
Naltrexone—Rash—Capecitabine—breast cancer	3.33e-05	0.000105	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—breast cancer	3.33e-05	0.000105	CcSEcCtD
Naltrexone—Dermatitis—Capecitabine—breast cancer	3.32e-05	0.000105	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—breast cancer	3.32e-05	0.000105	CcSEcCtD
Naltrexone—Headache—Capecitabine—breast cancer	3.31e-05	0.000105	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—breast cancer	3.3e-05	0.000105	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—breast cancer	3.3e-05	0.000104	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—breast cancer	3.29e-05	0.000104	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—breast cancer	3.28e-05	0.000104	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—breast cancer	3.27e-05	0.000103	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—breast cancer	3.24e-05	0.000103	CcSEcCtD
Naltrexone—Nausea—Docetaxel—breast cancer	3.24e-05	0.000102	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—breast cancer	3.24e-05	0.000102	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—breast cancer	3.21e-05	0.000102	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—breast cancer	3.2e-05	0.000101	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—breast cancer	3.17e-05	0.0001	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—breast cancer	3.17e-05	0.0001	CcSEcCtD
Naltrexone—Pain—Epirubicin—breast cancer	3.14e-05	9.95e-05	CcSEcCtD
Naltrexone—Constipation—Epirubicin—breast cancer	3.14e-05	9.95e-05	CcSEcCtD
Naltrexone—Nausea—Capecitabine—breast cancer	3.14e-05	9.92e-05	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—breast cancer	3.12e-05	9.87e-05	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—breast cancer	3.11e-05	9.83e-05	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—breast cancer	3.11e-05	9.83e-05	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.1e-05	9.81e-05	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—breast cancer	3.08e-05	9.73e-05	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—breast cancer	3.05e-05	9.66e-05	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—breast cancer	3.03e-05	9.6e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—breast cancer	3.03e-05	9.59e-05	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—breast cancer	3.02e-05	9.57e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—breast cancer	3.01e-05	9.51e-05	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—breast cancer	2.96e-05	9.36e-05	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—breast cancer	2.94e-05	9.29e-05	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—breast cancer	2.93e-05	9.28e-05	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—breast cancer	2.92e-05	9.24e-05	CcSEcCtD
Naltrexone—Pain—Doxorubicin—breast cancer	2.91e-05	9.2e-05	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—breast cancer	2.91e-05	9.2e-05	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—breast cancer	2.91e-05	9.2e-05	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—breast cancer	2.91e-05	9.2e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—breast cancer	2.89e-05	9.16e-05	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—breast cancer	2.82e-05	8.92e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—breast cancer	2.8e-05	8.87e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—breast cancer	2.78e-05	8.8e-05	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—breast cancer	2.78e-05	8.79e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—breast cancer	2.71e-05	8.57e-05	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—breast cancer	2.7e-05	8.55e-05	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—breast cancer	2.69e-05	8.51e-05	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—breast cancer	2.69e-05	8.51e-05	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—breast cancer	2.69e-05	8.5e-05	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—breast cancer	2.64e-05	8.35e-05	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—breast cancer	2.6e-05	8.23e-05	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—breast cancer	2.6e-05	8.22e-05	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—breast cancer	2.52e-05	7.96e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—breast cancer	2.51e-05	7.93e-05	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—breast cancer	2.5e-05	7.9e-05	CcSEcCtD
Naltrexone—Rash—Methotrexate—breast cancer	2.48e-05	7.84e-05	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—breast cancer	2.48e-05	7.83e-05	CcSEcCtD
Naltrexone—Headache—Methotrexate—breast cancer	2.46e-05	7.79e-05	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—breast cancer	2.44e-05	7.72e-05	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—breast cancer	2.43e-05	7.69e-05	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—breast cancer	2.41e-05	7.61e-05	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—breast cancer	2.34e-05	7.4e-05	CcSEcCtD
Naltrexone—Nausea—Methotrexate—breast cancer	2.33e-05	7.38e-05	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—breast cancer	2.33e-05	7.36e-05	CcSEcCtD
Naltrexone—Rash—Epirubicin—breast cancer	2.32e-05	7.33e-05	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—breast cancer	2.32e-05	7.33e-05	CcSEcCtD
Naltrexone—Headache—Epirubicin—breast cancer	2.3e-05	7.29e-05	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—breast cancer	2.25e-05	7.12e-05	CcSEcCtD
Naltrexone—Nausea—Epirubicin—breast cancer	2.18e-05	6.91e-05	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—breast cancer	2.16e-05	6.84e-05	CcSEcCtD
Naltrexone—Rash—Doxorubicin—breast cancer	2.15e-05	6.79e-05	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—breast cancer	2.14e-05	6.78e-05	CcSEcCtD
Naltrexone—Headache—Doxorubicin—breast cancer	2.13e-05	6.74e-05	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—breast cancer	2.02e-05	6.39e-05	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—SMAD4—breast cancer	1.24e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—breast cancer	1.23e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—breast cancer	1.23e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—breast cancer	1.22e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR1—breast cancer	1.22e-05	0.000104	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	1.22e-05	0.000104	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—breast cancer	1.21e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—breast cancer	1.2e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—breast cancer	1.2e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—breast cancer	1.2e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLA2G4A—breast cancer	1.2e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCOR1—breast cancer	1.2e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—breast cancer	1.2e-05	0.000102	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—breast cancer	1.2e-05	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MED12—breast cancer	1.2e-05	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DPYD—breast cancer	1.2e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—breast cancer	1.19e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF1—breast cancer	1.19e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—breast cancer	1.19e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—breast cancer	1.19e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRG1—breast cancer	1.18e-05	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOA—breast cancer	1.18e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—H2AFX—breast cancer	1.17e-05	0.0001	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—breast cancer	1.17e-05	0.0001	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—breast cancer	1.17e-05	9.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—E2F1—breast cancer	1.16e-05	9.93e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—breast cancer	1.16e-05	9.9e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—breast cancer	1.16e-05	9.89e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—breast cancer	1.15e-05	9.85e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—breast cancer	1.15e-05	9.79e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA3—breast cancer	1.14e-05	9.77e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A2—breast cancer	1.14e-05	9.7e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—breast cancer	1.13e-05	9.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—breast cancer	1.12e-05	9.54e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—breast cancer	1.12e-05	9.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTR—breast cancer	1.11e-05	9.51e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CPT1A—breast cancer	1.11e-05	9.51e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG2—breast cancer	1.11e-05	9.51e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—breast cancer	1.11e-05	9.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB3—breast cancer	1.11e-05	9.44e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR2—breast cancer	1.1e-05	9.42e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—breast cancer	1.1e-05	9.42e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—breast cancer	1.1e-05	9.42e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT2—breast cancer	1.1e-05	9.41e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—breast cancer	1.1e-05	9.37e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—breast cancer	1.09e-05	9.32e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HPGDS—breast cancer	1.09e-05	9.32e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKBIA—breast cancer	1.09e-05	9.31e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HBA1—breast cancer	1.08e-05	9.26e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—breast cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—breast cancer	1.06e-05	9.08e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—breast cancer	1.06e-05	9.05e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—breast cancer	1.06e-05	9.04e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACHE—breast cancer	1.06e-05	9.04e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—breast cancer	1.06e-05	9.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—breast cancer	1.06e-05	9.02e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—breast cancer	1.06e-05	9.02e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—breast cancer	1.06e-05	9.02e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—breast cancer	1.05e-05	8.96e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—breast cancer	1.05e-05	8.94e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—breast cancer	1.04e-05	8.91e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—breast cancer	1.04e-05	8.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR1—breast cancer	1.03e-05	8.78e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	1.03e-05	8.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—breast cancer	1.01e-05	8.65e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—breast cancer	1.01e-05	8.64e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP17A1—breast cancer	1e-05	8.56e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—breast cancer	1e-05	8.54e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—breast cancer	9.92e-06	8.48e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS1—breast cancer	9.92e-06	8.47e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—breast cancer	9.92e-06	8.47e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—breast cancer	9.89e-06	8.45e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—breast cancer	9.8e-06	8.37e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2D6—breast cancer	9.73e-06	8.31e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—breast cancer	9.69e-06	8.27e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—breast cancer	9.67e-06	8.26e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT2—breast cancer	9.66e-06	8.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—breast cancer	9.62e-06	8.22e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—breast cancer	9.59e-06	8.2e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA2—breast cancer	9.55e-06	8.16e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—breast cancer	9.52e-06	8.13e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—breast cancer	9.48e-06	8.1e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—breast cancer	9.47e-06	8.09e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—breast cancer	9.45e-06	8.07e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—breast cancer	9.44e-06	8.06e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RELA—breast cancer	9.41e-06	8.04e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—breast cancer	9.35e-06	7.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—breast cancer	9.32e-06	7.96e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—breast cancer	9.28e-06	7.93e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	9.28e-06	7.92e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FASN—breast cancer	9.26e-06	7.91e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—breast cancer	9.23e-06	7.88e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—breast cancer	9.23e-06	7.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—breast cancer	9.22e-06	7.88e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKBIA—breast cancer	9.21e-06	7.87e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—breast cancer	9.19e-06	7.85e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—breast cancer	9.18e-06	7.84e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—breast cancer	9.13e-06	7.79e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A5—breast cancer	9.11e-06	7.78e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—breast cancer	9.09e-06	7.76e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—breast cancer	9.06e-06	7.74e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—breast cancer	8.92e-06	7.62e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—breast cancer	8.92e-06	7.62e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—breast cancer	8.92e-06	7.62e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—breast cancer	8.87e-06	7.57e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—breast cancer	8.82e-06	7.53e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—breast cancer	8.81e-06	7.52e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A1—breast cancer	8.8e-06	7.51e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NQO1—breast cancer	8.8e-06	7.51e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—breast cancer	8.76e-06	7.49e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—breast cancer	8.66e-06	7.4e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP3A4—breast cancer	8.58e-06	7.33e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—breast cancer	8.57e-06	7.32e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—breast cancer	8.55e-06	7.3e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—breast cancer	8.49e-06	7.25e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—breast cancer	8.47e-06	7.24e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1B1—breast cancer	8.43e-06	7.2e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—breast cancer	8.43e-06	7.2e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	8.39e-06	7.17e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—breast cancer	8.39e-06	7.16e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—breast cancer	8.36e-06	7.14e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—breast cancer	8.35e-06	7.13e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—breast cancer	8.32e-06	7.1e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—breast cancer	8.29e-06	7.08e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—breast cancer	8.29e-06	7.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSP90AA1—breast cancer	8.27e-06	7.06e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—breast cancer	8.26e-06	7.06e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RELA—breast cancer	8.25e-06	7.05e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—breast cancer	8.24e-06	7.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—breast cancer	8.2e-06	7e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—breast cancer	8.18e-06	6.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—breast cancer	8.17e-06	6.98e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT2—breast cancer	8.16e-06	6.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—breast cancer	8.13e-06	6.94e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—breast cancer	8.09e-06	6.91e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—breast cancer	8.09e-06	6.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA1—breast cancer	8.05e-06	6.87e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—breast cancer	8.02e-06	6.85e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—breast cancer	7.99e-06	6.83e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—breast cancer	7.97e-06	6.81e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—STK11—breast cancer	7.93e-06	6.77e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP19A1—breast cancer	7.93e-06	6.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—breast cancer	7.84e-06	6.7e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—breast cancer	7.8e-06	6.66e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—breast cancer	7.78e-06	6.64e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—breast cancer	7.77e-06	6.64e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	7.77e-06	6.64e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—breast cancer	7.76e-06	6.63e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—breast cancer	7.72e-06	6.6e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—breast cancer	7.68e-06	6.56e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—breast cancer	7.59e-06	6.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—breast cancer	7.51e-06	6.42e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—breast cancer	7.44e-06	6.36e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—breast cancer	7.43e-06	6.35e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—breast cancer	7.41e-06	6.33e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—breast cancer	7.39e-06	6.32e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—breast cancer	7.39e-06	6.31e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—COMT—breast cancer	7.37e-06	6.3e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—breast cancer	7.34e-06	6.27e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—breast cancer	7.24e-06	6.19e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—breast cancer	7.24e-06	6.18e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—breast cancer	7.23e-06	6.17e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—breast cancer	7.23e-06	6.17e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ITPR1—breast cancer	7.22e-06	6.17e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—breast cancer	7.2e-06	6.15e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—breast cancer	7.17e-06	6.13e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—breast cancer	7.13e-06	6.09e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	7.06e-06	6.03e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—breast cancer	7.03e-06	6.01e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—breast cancer	7.03e-06	6e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—breast cancer	7.01e-06	5.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—breast cancer	7e-06	5.98e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—breast cancer	6.99e-06	5.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RELA—breast cancer	6.97e-06	5.96e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—breast cancer	6.93e-06	5.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—breast cancer	6.84e-06	5.84e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—breast cancer	6.84e-06	5.84e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—breast cancer	6.84e-06	5.84e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—breast cancer	6.82e-06	5.83e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—breast cancer	6.82e-06	5.83e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—breast cancer	6.81e-06	5.82e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOR1—breast cancer	6.74e-06	5.76e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—breast cancer	6.74e-06	5.76e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G4A—breast cancer	6.74e-06	5.76e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—breast cancer	6.63e-06	5.66e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—breast cancer	6.61e-06	5.65e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—breast cancer	6.57e-06	5.61e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—breast cancer	6.53e-06	5.58e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—breast cancer	6.48e-06	5.54e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—breast cancer	6.48e-06	5.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—breast cancer	6.46e-06	5.52e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—breast cancer	6.42e-06	5.48e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—breast cancer	6.39e-06	5.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—breast cancer	6.35e-06	5.42e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—breast cancer	6.34e-06	5.41e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—breast cancer	6.31e-06	5.39e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—breast cancer	6.29e-06	5.37e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—breast cancer	6.28e-06	5.36e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—breast cancer	6.25e-06	5.34e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—breast cancer	6.25e-06	5.34e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—breast cancer	6.12e-06	5.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—breast cancer	6.12e-06	5.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—breast cancer	6.11e-06	5.22e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—breast cancer	6.06e-06	5.18e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—breast cancer	5.97e-06	5.1e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—breast cancer	5.96e-06	5.09e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—breast cancer	5.94e-06	5.08e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—breast cancer	5.92e-06	5.06e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—breast cancer	5.91e-06	5.05e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—breast cancer	5.81e-06	4.96e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—breast cancer	5.8e-06	4.95e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—breast cancer	5.78e-06	4.94e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—breast cancer	5.76e-06	4.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—breast cancer	5.68e-06	4.85e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—breast cancer	5.62e-06	4.8e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—breast cancer	5.5e-06	4.69e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—breast cancer	5.48e-06	4.68e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—breast cancer	5.44e-06	4.65e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—breast cancer	5.37e-06	4.59e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—breast cancer	5.34e-06	4.56e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—breast cancer	5.28e-06	4.51e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—breast cancer	5.2e-06	4.44e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—breast cancer	5.1e-06	4.35e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—breast cancer	5.05e-06	4.31e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—breast cancer	5.01e-06	4.28e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—breast cancer	4.98e-06	4.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—breast cancer	4.93e-06	4.21e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—breast cancer	4.91e-06	4.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—breast cancer	4.9e-06	4.18e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—breast cancer	4.8e-06	4.1e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—breast cancer	4.77e-06	4.08e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—breast cancer	4.59e-06	3.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—breast cancer	4.56e-06	3.9e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—breast cancer	4.54e-06	3.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—breast cancer	4.4e-06	3.76e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—breast cancer	4.37e-06	3.73e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—breast cancer	4.34e-06	3.71e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—breast cancer	4.17e-06	3.56e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—breast cancer	4.16e-06	3.56e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—breast cancer	4.16e-06	3.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—breast cancer	4.03e-06	3.44e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—breast cancer	4.03e-06	3.44e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—breast cancer	3.86e-06	3.29e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—breast cancer	3.84e-06	3.28e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—breast cancer	3.8e-06	3.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—breast cancer	3.69e-06	3.15e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—breast cancer	3.41e-06	2.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—breast cancer	3.31e-06	2.83e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—breast cancer	2.34e-06	2e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—breast cancer	1.91e-06	1.63e-05	CbGpPWpGaD
